PHR.NYSEPhreesia, INC
10-K: Phreesia Reports Fiscal Year 2025 Results: Revenue Up 18%, Adjusted EBITDA Turns Positive
Sentiment:
Annual Results
Phreesia, a healthcare software solutions provider, announced an 18% increase in total revenue for fiscal year 2025, reaching $419.8 million, and a shift to positive adjusted EBITDA of $36.8 million.
Delay expectedThe implementation cycle is variable, typically ranging from one to 24 months from contract execution to completion of implementation.
Better than expectedThe company's adjusted EBITDA turned positive, a significant improvement from the previous year.The company's net loss decreased significantly from the previous year.The company's cash flow from operations improved from negative to positive.
Summary
- Phreesia, Inc., a leading provider of healthcare software solutions, reported its financial results for the fiscal year ended January 31, 2025.
- Total revenue increased by 18% to $419.8 million, compared to $356.3 million in the previous fiscal year.
- The company's net loss decreased significantly from $136.9 million in fiscal 2024 to $58.5 million in fiscal 2025.
- Adjusted EBITDA turned positive, reaching $36.8 million, a substantial improvement from a negative $35.4 million in the prior year.
- Cash provided by operating activities was $32.4 million, a turnaround from cash used in operating activities of $32.4 million in the previous year.
- Free cash flow was $8.3 million, compared to a negative $57.5 million in the prior year.
- The company's cash and cash equivalents totaled $84.2 million as of January 31, 2025.
- Subscription and related services revenue increased by 19% to $196.5 million.
- Payment processing fees revenue increased by 8% to $101.7 million.
- Network solutions revenue increased by 26% to $121.6 million.
- The company's average number of healthcare services clients (AHSCs) increased by 17% to 4,203.
- Healthcare services revenue per AHSC decreased slightly by 2% to $70,961.
- Total revenue per AHSC increased by 1% to $99,884.
- The company estimates its current addressable market is approximately $10.0 billion.
Sentiment
Score: 7
Explanation: The document presents a mixed picture. While revenue growth and improved profitability are positive, the company still faces challenges and risks. The overall sentiment is cautiously optimistic.
Positives
- Significant improvement in profitability with a shift to positive adjusted EBITDA.
- Strong revenue growth driven by increases in subscription, payment processing, and network solutions.
- Positive cash flow from operations and improved free cash flow.
- Increase in the number of healthcare services clients.
- Growth in Network Solutions revenue indicates successful engagement with life sciences companies and other organizations.
Negatives
- The company still reported a net loss, although it was significantly reduced from the previous year.
- Healthcare services revenue per AHSC decreased slightly by 2%.
Risks
- The company operates in a highly competitive industry.
- Failure to manage future growth effectively could hinder revenue increases.
- Privacy concerns and cybersecurity incidents could lead to economic loss and reputational damage.
- Operations in India are subject to additional risks.
- The company incurs significant upfront costs in client relationships.
- Variable sales and implementation cycles can lead to fluctuations in quarterly results.
- Estimates of the target market size may prove inaccurate.
- The company depends on senior management and key employees.
- Acquisitions and investments may be difficult to integrate.
- The company is subject to healthcare and data privacy laws.
- Reliance on third-party contractors, vendors, and partners poses risks.
Future Outlook
The company intends to continue to make significant investments to support business growth, develop new applications and services, enhance existing solutions, enhance operating infrastructure, and potentially acquire complementary businesses and technologies.
Industry Context
The company operates in the healthcare information technology industry, which is characterized by rapid technological advancements, evolving regulatory requirements, and increasing demand for patient engagement and consumerism. The company competes with both direct competitors focused on patient intake and indirect competitors such as EHR and PM system providers.
Comparison to Industry Standards
- The document does not provide a direct comparison to industry standards.
- However, it mentions competition with EHR and PM systems, suggesting that companies like Epic, Cerner, and Allscripts are competitors in certain aspects of the business.
- The document also mentions competition in life sciences marketing, which includes traditional media platforms and web-based platforms.
Legal Proceedings
- A putative class action complaint was filed against ConnectOnCall.com, LLC and Phreesia, Inc., in the United States District Court for the Eastern District of New York.
- Around the same time as the ConnectOnCall Case was filed, 12 additional putative class action complaints arising from the ConnectOnCall incident were filed in the United States District Court for the Eastern District of New Yorkagainst ConnectOnCall.com, LLC, Phreesia, Inc., or a combination of bothpurporting to represent the same nationwide class of individuals and asserting substantially the same claims.
Related Party Transactions
- The Company recognized revenue totaling $1,343 and $1,174 for the years ended January 31, 2025 and 2024, respectively, for advertisements placed by a pharmaceutical company where one of the Company's independent members of its board of directors serves on the board of directors.
- For the year ended January 31, 2024, the Company recognized general and administrative expenses totaling $118 for software agreements with a software company where one of the Company's independent members of its board of directors served as the chief executive officer and on the board of directors until May 2023.
Stakeholder Impact
- The company's performance impacts shareholders through stock value and potential dividends.
- Employees are affected by compensation, benefits, and job security.
- Customers (healthcare providers) benefit from improved software solutions and operational efficiency.
- Patients benefit from improved healthcare engagement and outcomes.
- Life sciences companies and other organizations benefit from a channel for direct communication with patients.
Next Steps
- The company intends to continue to proactively grow the business through expanding solutions to new healthcare services organizations.
- The company intends to deepen relationships with existing healthcare services clients.
- The company intends to continue to innovate and leverage solutions.
- The company intends to pursue opportunistic strategic investments, partnerships and acquisitions.
- The company intends to enhance margins through continued strategic growth.
Key Dates
| Date | Description |
|---|---|
| 1996 | Reference to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) |
| 2003 | Reference to the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (CAN-SPAM Act) |
| 2005 | Phreesia, Inc. was formed in May 2005. |
| 2008 | The Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code on February 20, 2008. |
| 2010 | Reference to the U.K. Bribery Act 2010. |
| 2017 | Reference to the Tax Cuts and Jobs Act of 2017. |
| 2018 | The Board of Directors adopted the Companys 2018 Stock Option Plan in January 2018. |
| 2018 | The EU adopted the General Data Protection Regulation (EU GDPR) in May 2018. |
| 2018 | Reference to Board Chairman Agreement, dated as of December 2018, by and between the Registrant and Michael Weintraub. |
| 2019 | The Company entered into the Amended and Restated Loan and Security Agreement in February 2019. |
| 2019 | The Board of Directors adopted the Companys 2019 Stock Option and Incentive Plan in June 2019. |
| 2019 | The Board of Directors adopted the Company's 2019 Employee Stock Purchase Plan in June 2019. |
| 2019 | The Company closed its initial public offering (IPO) on July 22, 2019. |
| 2020 | The Company entered into the Second Amended and Restated Loan and Security Agreement in May 2020. |
| 2020 | Reference to The Coronavirus Aid, Relief, and Economic Security Act of 2020. |
| 2020 | The HHS, ONC and CMS promulgated final rules to clarify and operationalize provisions of the 21st Century Cures Act in 2020. |
| 2021 | The Company entered into the First Loan Modification Agreement to the Second SVB Facility in March 2022. |
| 2022 | Reference to Third Amended and Restated Non-Employee Director Compensation Policy, dated June 2022. |
| 2022 | Reference to the Inflation Reduction Act of 2022. |
| 2023 | The CPRA amendments to the CCPA went into effect on January 1, 2023. |
| 2023 | The Company entered into a financing agreement in June 2023. |
| 2023 | The Company entered into an agreement to acquire 100% of the outstanding equity of Comsort, Inc. d/b/a MediFind on June 30, 2023. |
| 2023 | The Board of Directors adopted the Companys 2023 Inducement Award Plan in July 2023. |
| 2023 | The Company entered into an agreement to acquire 100% of the outstanding equity of Access eForms, LLC on August 11, 2023. |
| 2023 | The Company entered into an agreement to acquire 100% of the outstanding equity of ConnectOnCall on October 3, 2023. |
| 2023 | The Company entered into a 5-year $50 million senior secured asset-based revolving credit facility in December 2023. |
| 2024 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2024 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule on December 27, 2024. |
| 2025 | The HHS-OCR issued a Notice of Proposed Rulemaking to modify the HIPAA Security Rule to enhance cybersecurity protections for electronic protected health information (ePHI) on December 27, 2024. |
| 2025 | As of January 31, 2025, the Company had U.S. federal and state net operating loss carryforwards (NOLs) of $596.5 million. |
| 2025 | On March 12, 2025, the Board of Directors authorized a stock repurchase program. |
| 2025 | Michael Weintraub, a member of the Companys Board of Directors, adopted a trading arrangement for the sale of securities of the Companys common stock on January 6, 2025. |
| 2025 | Amy VanDuyn, the Senior Vice President, Human Resources of the Company, adopted a Rule 10b5-1 Trading Plan on January 10, 2025. |
| 2025 | Mark Smith, a member of the Companys Board of Directors, adopted a Rule 10b5-1 Trading Plan on January 10, 2025. |
| 2025 | David Linetsky, the Senior Vice President, Life Sciences of the Company, adopted a Rule 10b5-1 Trading Plan on January 15, 2025. |
| 2026 | Several states, including Colorado and California, passed laws that will take effect in 2026 to regulate various uses of artificial intelligence, including to make consequential decisions. |
| 2028 | The Capital One Credit Facility matures in December 2028. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.